A recent study evaluates the overall benefits of all-new combination therapy for the treatment of metastatic colorectal cancer.
An all-new study has revealed that the utilization of specialized combination therapy for the treatment of metastatic colorectal cancer can prove highly promising in the coming era. The study aims at analyzing as well as presenting the potential benefits of the combination therapy for treating patients having BRAF-mutant metastatic form of colorectal cancer. It is observed that around 10 percent of patients having metastatic colorectal cancer tend to have BRAF mutation. This type of colorectal cancer is known to signify a poor prognosis during the initial treatment for metastatic colorectal cancer that is BRAF-mutated. This results into poor outcomes of the treatments with the next line treatments having minimal effects.
Evidence from recent studies has identified that inhibiting the pathway of BRAF-mutated cancer cells is not enough during the treatment phase. This fact explains the lackluster of the overall clinical efficacy that is observed with the recent series of treatments associated with the therapy of BRAF-mutations in colorectal cancer.
However, at the same time, BRAF inhibitors have shown to deliver more effective results against major cancer activity. This holds true when the actions of the BRAF inhibitors have been combined with the anti-EGFR monoclonal antibody. This fact was demonstrated during the initial phases of the clinical trials with respect to cancer treatment. Moreover, initial trials of the triple combination treatment, including a MEK inhibiting agent has revealed promising results against the metastatic colorectal cancer with BRAF-mutations.
The Study Involving an All-new Therapy
A study was conducted to analyze whether or not the given triple therapy combination will help in improving the overall survival of the patients having metastatic colorectal cancer with BRAF mutations. For the same, a team of researchers was responsible for designing as well as conducting the trials involving BEACON CRC –standing for Binimetinib, Encorafenib, and Cetuximab for the treatment of BRAF-mutant Colorectal Cancer. The results of the study by the given team of researchers were published in the journal, namely “New England Journal of Medicine.”
About BEACON CRC
BEACON CRC is a famous global-level, phase three, multi-center, randomized trial, including 665 patients having metastatic colorectal cancer with BRAF mutations. These patients, during the study, had received failure in the overall treatments – either during the first or second treatment lines. The patients during the trial were randomized to one of the available three groups of treatments. These groups were:
- Triple Therapy Group –the patients, receiving treatment from binimetinib, encorafenib, and Cetuximab
- Double Therapy Group –the patients receiving treatment from Cetuximab and encorafenib
- Control Group –a standard treatment of the choice of the investigator
The Findings of the Study
The findings of the study reported a significant value of around 48 percent reduced risks of death associated with the triple therapy group in comparison to the single control group. At the same time, it was observed that the median survival rate for the patients involved in the triple therapy group was as much as 9 months in comparison to 5.4 months of survival rate in the control group patients.
The researchers also observed a higher objective rate of response in the patients under the triple therapy group (around 26 percent) with the double therapy group patients representing 20 percent response and merely 2 percent response in patients under the control group. A longer duration before the stage of disease progression was observed in the patients involved in the triple & double therapy groups at a median of around 4.3 & 4.2 months, respectively. At the same time, the patients involved in the control groups were observed to signify the median result of just around 1.5 months.
As far as the overall adverse effects of the therapy treatments were concerned, it was as expected amongst the patients in the three subsequent groups for the given drug profiles. The groups involved in the combination therapy did not observe higher toxicity or even deaths in comparison to the patients undergoing the control therapy.
The early analysis, as well as demonstration of the results of the BEACON CRC trial, revealed a longer survival rate along with the higher objective rate of response. This was observed to be possible in cases of combination therapy –the triple therapy treatments involving the combination of drugs, namely Cetuximab, encorafenib, and binimetinib. This was quite significant in comparison to the standard or control therapy treatment.
The results of the given are observed to be highly promising for the future of the available treatment options for improving the overall outcomes for the patients having metastatic colorectal cancer with BRAF mutation. The benefits of the combination of triple therapy treatment options are expected to be further studied during upcoming trials.